可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] 田建伟,刘朝中,江一清. 血小板糖蛋白(GP) IIb/IIIa受体拮抗剂及在冠心病临床应用的研究进展[J]. 心脏杂志,2000,12(4):306-308.
[2] Blankenship JC.Bleeding complications of glycoprotein IIb/IIIa receptor inhibitors[J]. Am Heart J,1999,138(4 pt 2):287-296.
[3] A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Study Investigators [J]. N Engl J Med,1998,338 (21):1498-1505.
[4] Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and nonQwave myocardial infarction. Platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms(PRISMPLUS) study investigators[J]. N Engl J Med,1998,338(21): 1488-1497.
[5] Effects of platelet glycoprotein IIb/IIIa blockage with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. The RESTORE Investigators. Randomized Ehicacy study of Tirofiban for Outcomes and Restenosis [J]. Circulation,1997,96(5):1445-1453.
[6] Karvouni E, Katritsis DG, Ioannidis JP. Intravenous glycoprotein IIb/IIIa receptor antagonists reduce mortality after percutaneous coronary interventions[J].J Am Coll Cardiol, 2003,41(1):26-32.
[7] 彭黎明,邓承祺. 现代血栓与止血的实验室检测及其应用[M].北京:人民卫生出版社,2004.